S.F. 307 Section 1. Section 514F.7, subsection 1, Code 2023, is 1 amended by adding the following new paragraphs: 2 NEW PARAGRAPH . 0b. “Biological product” means the same as 3 defined in section 155A.3. 4 NEW PARAGRAPH . 00b. “Biosimilar” means the same as defined 5 in 42 U.S.C. §262. 6 NEW PARAGRAPH . 0i. “Interchangeable” means the same as 7 defined in 42 U.S.C. §262. 8 NEW PARAGRAPH . 00i. “Interchangeable biological product” 9 means the same as defined in section 155A.3. 10 Sec. 2. Section 514F.7, subsection 4, paragraph a, Code 11 2023, is amended to read as follows: 12 a. Prevent a health carrier, health benefit plan, or 13 utilization review organization from requiring a covered person 14 to try a prescription drug with the same generic name and 15 demonstrated bioavailability , or a biological product that 16 is an interchangeable biological product pursuant to section 17 155A.32 , or an interchangeable biosimilar prior to providing 18 coverage for the equivalent branded prescription drug. 19 EXPLANATION 20 The inclusion of this explanation does not constitute agreement with 21 the explanation’s substance by the members of the general assembly. 22 This bill relates to step therapy protocols and 23 interchangeable biosimilars. 24 Under current law, a health carrier, health benefit plan, or 25 utilization review organization may require a covered person 26 (person) to try a prescription drug (drug) with the same 27 generic name and demonstrated bioavailability, or a biological 28 product that is an interchangeable biological product, prior to 29 providing coverage for an equivalent branded drug. The bill 30 allows a health carrier, health benefit plan, or utilization 31 review organization to also require a person to try an 32 interchangeable biosimilar prior to providing coverage for an 33 equivalent branded drug. “Biosimilar” and “interchangeable” 34 are defined in the bill. 35 -1- LSB 2200XS (4) 90 ko/rn 1/ 1